

CITATION REPORT

List of articles citing

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors

DOI: 10.1007/s00280-005-0134-0

Cancer Chemotherapy and Pharmacology, 2006, 58, 107-16.

Source: <https://exaly.com/paper-pdf/40687648/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	The development of targeted therapies for hepatocellular cancer. <i>Current Pharmaceutical Design</i> , 2007 , 13, 3292-300	3.3	7
7	Farnesyltransferase inhibitors: where are we now?. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1569-80	5.9	33
6	Farnesyltransferase Inhibitor in Cancer Treatment. 2011 ,		
5	KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 530-42	8.9	84
4	New Therapeutic Strategies in Lung Cancers. 2015 ,		0
3	Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. <i>Advanced Drug Delivery Reviews</i> , 2020 , 159, 245-293	18.5	96
2	Pan-HER Inhibitors. 2007 , 67-76		
1	Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer. 2015 , 157-185		